CGON.O - | Stock Price & Latest News | Reuters

6 days ago · Get CG Oncology Inc (CGON.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments

CouponFollow Extension

6%
OFF

Cancer Drug Developer CG Oncology Valued At $1.75 Bln In Strong …

20 hours ago

Jan 25 (Reuters) - Cancer drug developer CG Oncology , opens new tab notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as …

reuters.com

$306
OFF

UPDATE 2-Drug Developer CG Oncology Targets Up To $306 Mln …

20 hours ago

Jan 23 (Reuters) - Cancer drug developer CG Oncology said on Tuesday it was aiming to raise up to $306 million in its upsized initial public offering in New York, underscoring the resurgent …

yahoo.com

6%
OFF

Cancer Drug Developer CG Oncology Valued At $1.75 Billion In …

20 hours ago

Jan 25, 2024 · (Reuters) -Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as new …

usnews.com

$306
OFF

Drug Developer CG Oncology Targets Up To $306 Mln For Upsized IPO

20 hours ago

Jan 23, 2024 · Adds background, IPO detail in paragraphs 2-6. Jan 23 (Reuters) - Cancer drug developer CG Oncology said on Tuesday it was aiming to raise up to $306 million in its U.S. …

nasdaq.com

$1
OFF

CG Oncology Targets Near $1 Bln Valuation In US IPO | Reuters

20 hours ago

Jan 18 (Reuters) - Cancer drug developer CG Oncology said on Thursday it was targeting a valuation of nearly $1 billion for its initial public offering. The company is developing a therapy …

reuters.com

$380
OFF

CG Oncology Prices Larger-than-expected $380M IPO In Hopeful …

20 hours ago

Jan 24, 2024 · Cancer drug developer CG Oncology has raised $380 million in an initial public offering than was larger than it expected, a positive sign for a sector that’s struggled to …

biopharmadive.com

FAQs about CGON.O - | Stock Price & Latest News | Reuters Coupon?

How much is CG oncology worth?

Jan 25 (Reuters) - Cancer drug developer CG Oncology (CGON.O) notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as new listings pick up pace. ...

Will CG oncology raise $306 million?

Jan 23 (Reuters) - Cancer drug developer CG Oncology said on Tuesday it was aiming to raise up to $306 million in its U.S. initial public offering, higher than it had previously expected. ...

Who is CG oncology?

Post. CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. ...

Is CG oncology a good IPO?

Biotech stocks have fallen about 1% so far this year. With a lead asset in advanced Phase-III testing, CG Oncology, which debuts Thursday on the NASDAQ, is one of the year's most highly anticipated IPOs. The company's lead drug targets a sizable addressa... ...

Will CG Oncology GO Public?

The firm aims to list on the Nasdaq under the symbol CGON. CG Oncology has filed to go public with an IPO on the NASDAQ. CG Oncology has received fast track designation and breakthrough designation needed to accelerate US FDA submission. ...

Who are CG oncology's biggest shareholders?

Biotech investor ORI Capital and life sciences investor Decheng Capital are its biggest shareholders. CG Oncology is one of a handful of companies from the healthcare sector looking to list in the coming months, as a market rally on hopes of a soft landing for the economy eases pressure on startups looking to go public. ...